BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Acute myeloid leukemia with CEBPA double-mutations harbors in 76.8% of cases concomitant molecular mutations with TET2 and GATA2...

Dataset: Acute myeloid leukemia with CEBPA double-mutations harbors in 76.8% of cases concomitant molecular mutations with TET2 and GATA2 alterations demonstrating strong prognostic impact

Acute myeloid leukemia (AML) with CEBPA mutations is determined as provisional entity in the current WHO. A difference in clinical...

Registered by ArrayExpress Uploader
View Dataset

Acute myeloid leukemia (AML) with CEBPA mutations is determined as provisional entity in the current WHO. A difference in clinical outcome between single- (sm) and double-mutated (dm) cases has been reported, whereupon dm cases were shown to be associated with longer overall survival (OS). The occurrence and prognostic impact of concomitant molecular mutations in addition to CEBPAdm has not been assessed until now. Here, we investigated a cohort of 95 AML CEBPAdm cases for concomitant mutations. TET2 was found to be the most frequent mutation (32/94, 34.0%), followed by GATA2 (20/95, 21.0%), WT1 (13/95, 13.7%), DNMT3A (9/94, 9.6%), ASXL1 (9/95, 9.5%), NRAS (8/95, 8.4%), KRAS (3/94, 3.2%), IDH1/2 (6/95, 6.3%), FLT3-ITD (6/95, 6.3%), FLT3-TKD (2/95, 2.1%), NPM1 (2/95, 2.1%), and RUNX1 (1/94). No mutation was detected in MLL-PTD and TP53. With respect to prognostic impact, we observed that those cases harboring additional mutations in TET2 showed significant worse survival than wild-type cases (P=0.035), whereas GATA2 mutated cases showed improved survival (P=0.032). Further, using gene expression microarray analysis we identified no clear different clustering within the CEBPAdm cases with the distinct concomitant mutated genes. In conclusion, we demonstrated that 76.8% of CEBPAdm cases harbored additional alterations in other molecular markers and that CEBPA is a suitable MRD marker to control therapy. Total cohort contains 95 cases, but expression data available for 38 cases which were analyzed on Affymetrix HG-U133 Plus 2.0 arrays: 8 CEBPAdm and GATA2 mutated cases, 12 CEBPAdm and TET2 mutated cases, 7 CEBPAdm and ASXL1 mutated cases (n=3 showed an additional TET2 mutation) and 11 CEBPAdm without mutations in GATA2, TET2, and ASXL1.

Species:
human

Samples:
38

Source:
E-GEOD-42064

PubMed:
23521373

Updated:
Dec.12, 2014

Registered:
Jul.12, 2014


Factors: (via ArrayExpress)
Sample CASE MUTATION
GSM1031868 MLL_00361 GATA2 mut
GSM1031867 MLL_00360 GATA2 mut
GSM1031866 MLL_00359 GATA2 mut
GSM1031865 MLL_00358 GATA2 mut
GSM1031864 MLL_00355 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031863 MLL_00354 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031862 MLL_00353 ASXL1/GATA2/TET2/DNMT3A wt
GSM103186 MLL_00352 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031860 MLL_00351 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031859 MLL_00350 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031858 MLL_00349 TET2 mut
GSM1031857 MLL_00348 TET2 mut
GSM1031856 MLL_00347 TET2 mut
GSM1031855 MLL_00346 TET2 mut
GSM1031854 MLL_00345 TET2 mut
GSM1031853 MLL_00344 TET2 mut
GSM1031852 MLL_00343 TET2 mut
GSM103185 MLL_00342 TET2 mut
GSM1031850 MLL_00341 TET2 mut
GSM1031849 MLL_00340 TET2 mut
GSM1031848 MLL_00339 TET2 mut
GSM1031847 MLL_00338 TET2 mut
GSM1031846 MLL_00337 GATA2 mut
GSM1031845 MLL_00336 GATA2 mut
GSM1031844 MLL_00335 GATA2 mut
GSM1031843 MLL_00334 GATA2 mut
GSM1031842 MLL_00333 ASXL1/GATA2/TET2/DNMT3A wt
GSM103184 MLL_00332 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031840 MLL_00331 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031839 MLL_00330 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031838 MLL_00329 ASXL1/GATA2/TET2/DNMT3A wt
GSM1031837 MLL_00328 ASXL1 mut/ TET2 mut
GSM1031836 MLL_00327 ASXL1 mut/ TET2 mut
GSM1031835 MLL_00326 ASXL1 mut/ TET2 mut
GSM1031834 MLL_00325 ASXL1 mut
GSM1031833 MLL_00324 ASXL1 mut
GSM1031832 MLL_00323 ASXL1 mut
GSM103183 MLL_00322 ASXL1 mut

Tags

  • acute myeloid leukemia
  • leukemia
  • myeloid leukemia
  • wt1

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use